titleOfInvention |
hematopoietic stem cell, hematopoietic progenitor cell, myeloid/monocyte-compromised progenitor cell, macrophage or monocyte, tumor-associated antigen-specific t-cell, immune checkpoint inhibitor, 1-methyl-tryptophan, combination of a point inhibitor checkpoint and a tumor-associated antigen-specific t-cell, method for treating or preventing a cancer, and, hematopoietic stem cell population, hematopoietic progenitor cells, myeloid/monocyte-compromised progenitor cells, macrophages, or monocytes. |
abstract |
a hematopoietic stem cell (hsc), a hematopoietic progenitor cell (hpc), a myeloid/monocyte-compromised progenitor cell, a macrophage or a monocyte comprising a vector wherein the vector comprises at least a mir-130a and/or mir target sequence -126 functionally linked to an interferon-alpha (ifnalpha) encoding nucleotide sequence for use in treating or preventing a cancer in a patient, wherein the hsc, the hpc, the myeloid/monocyte-compromised progenitor cell, the macrophage or the monocyte is used in combination with an immune checkpoint inhibitor and/or a tumor-associated antigen (taa)-specific t-cell. |